Investment Rating - The report maintains an "Accumulate" rating for the in vitro diagnostics industry [7]. Core Views - The in vitro diagnostics (IVD) market is experiencing significant growth, with the domestic biochemical diagnostics sector having largely completed its localization process. The report suggests focusing on the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [4][54]. - Recent policy changes in Chongqing regarding pathology service pricing are expected to streamline and clarify pricing structures, which may enhance the role of pathology in precision medicine [4][54]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 7.81% this week, ranking 6th among 31 primary industries. The in vitro diagnostics sector specifically increased by 8.52% [9][18]. - The medical services sub-sector reported a 12.34% increase, while other related sectors also showed positive growth [18][19]. Valuation Metrics - As of the end of the week, the in vitro diagnostics sector had a PE ratio of 41.66X, with a one-year maximum of 41.97X and a minimum of 20.96X. The current PB ratio stands at 1.90X, with a one-year maximum of 2.01X and a minimum of 1.53X [3][28]. - The PE ratio increased by 3.30X and the PB ratio by 0.15X compared to the previous week [28]. Company Performance - Top-performing companies in the medical services sector include Anbiping (+39.5%), Rejing Biological (+27.1%), and Botuo Biological (+19.0%). Conversely, Mingde Biological (-2.2%) and others showed weaker performance [2][23].

Summary of Key Points Core Viewpoint - The announcement details the results of a share reduction plan executed by major shareholders of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., indicating a complete execution of the planned share reduction. Group 1: Shareholder Holdings - Prior to the reduction plan, shareholders including Zhuhai Gaotejia Ruian Investment Partnership and its concerted actions held a total of 6,292,662 shares, representing 6.7253% of the company's total equity [2]. Group 2: Implementation of Reduction Plan - On November 6, 2025, the company disclosed a share reduction plan allowing the aforementioned shareholders to reduce their holdings by up to 935,676 shares, which is 1.00% of the total equity [3]. - The shareholders successfully reduced their holdings by exactly 935,676 shares, meeting the planned reduction target [3]. - The reduction was conducted in compliance with relevant laws and regulations, and there were no violations of the reduction plan or other commitments [3].

| 买入营业部名称 | 买入金额(万元) | | --- | --- | | 国泰海通证券股份有限公司总部 | 2435.37 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 2182.46 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 1600.87 | | 国泰海通证券股份有限公司上海长宁区江苏路证券营业部 | 1383.52 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1222.58 | | 卖出营业部名称 | 卖出金额(万元) | | 中国银河证券股份有限公司广州东风中路证券营业部 | 1841.21 | | 国泰海通证券股份有限公司总部 | 979.56 | | 国泰海通证券股份有限公司汕头长平路证券营业部 | 974.73 | | 机构专用 | 901.82 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 871.01 | 1月9日安必平（688393）收盘价33.04元，收盘上涨19.71%，全天换手率16.78%，振幅14.33%，成交额 4.91亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 （文章 ...

Group 1 - OpenAI has launched ChatGPT Health, a dedicated health assistant that allows users to connect personal medical records and health applications for tailored responses [1][2] - Over 230 million people globally consult ChatGPT for health-related inquiries each week, indicating strong demand for AI health tools [1][2] - ChatGPT Health features a separate storage mechanism to ensure health conversations and data are isolated from other chat records, emphasizing its role as an auxiliary tool rather than a diagnostic or treatment solution [1][2] Group 2 - Users can securely connect various data sources, including electronic health records and mainstream health apps, enabling personalized health insights based on individual health data [2] - The introduction of ChatGPT Health reflects the deepening penetration of AI into personal health management, potentially alleviating some pressure on healthcare systems [2] - The global AI healthcare market is projected to approach $40 billion by 2025 and exceed $500 billion by 2032, with a compound annual growth rate of over 40% [3] Group 3 - The launch of ChatGPT Health aligns with the trend of integrating fragmented health data into a single conversational interface, lowering the barrier to information access [3] - Major Chinese tech companies are rapidly entering the AI health sector, with various products competing for user attention [3] - The capital market reacted positively to the AI health sector, with significant stock price increases for companies involved in AI healthcare applications [4]

（文章来源：证券日报） 证券日报网讯 1月9日，安必平发布公告称，诸暨高特佳、重庆高特佳、杭州高特佳、杭州睿泓等一致 行动人于2025年12月1日至2026年1月9日通过集中竞价合计减持安必平935676股，占总股本1.00%，减 持计划已实施完毕。 ...

Group 1 - The medical device sector increased by 1.47% on January 9, with Anbiping leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] - Anbiping's stock price rose by 19.71% to 33.04, with a trading volume of 157,000 shares and a transaction value of 491 million yuan [1] Group 2 - The medical device sector experienced a net outflow of 629 million yuan from institutional investors, while retail investors saw a net inflow of 797 million yuan [2] - The top gainers in the medical device sector included Huada Zhizao, which rose by 10.21% to 75.00, and Jigaofazhan, which increased by 10.16% to 3.47 [1] - The top losers included Meihua Medical, which fell by 11.81% to 37.55, and Yuanpeng Medical, which decreased by 8.66% to 38.93 [2] Group 3 - The net inflow of funds for Yuyue Medical was 96.43 million yuan, while it faced a net outflow of 63.12 million yuan from retail investors [3] - Jigaofazhan had a net inflow of 71.09 million yuan from institutional investors, with a net outflow of 41.66 million yuan from retail investors [3] - Anbiping saw a net inflow of 37.38 million yuan from institutional investors, while retail investors experienced a net outflow of 15.65 million yuan [3]

格隆汇1月9日丨安必平(688393.SH)公布，今日，公司收到股东诸暨高特佳、重庆高特佳、杭州高特佳 和杭州睿泓出具的《股份减持结果告知函》，上述主体通过集中竞价交易的方式合计减持93.57万股， 占公司总股本的1.00%。 ...

2026年1月10日，广州安必平医药科技股份有限公司（以下简称"安必平"）发布股东减持股份结果公 告，披露诸暨高特佳睿安投资合伙企业（有限合伙）（以下简称"诸暨高特佳"）及其一致行动人已完成 此前披露的减持计划，合计减持公司股份93.57万股，占公司总股本的1.00%。 减持计划背景：IPO前股东集体减持 公告显示，本次减持计划实施前，诸暨高特佳及其一致行动人重庆高特佳睿安股权投资基金合伙企业 （有限合伙）（以下简称"重庆高特佳"）、杭州高特佳睿海投资合伙企业（有限合伙）（以下简称"杭 州高特佳"）、杭州睿泓投资合伙企业（有限合伙）（以下简称"杭州睿泓"）及董事王海蛟先生合计持 有安必平629.27万股，占公司总股本的6.7253%。上述股份均为公司首次公开发行（IPO）前取得，并已 于2021年8月20日解除限售上市流通。 2025年11月6日，安必平披露《股东减持股份计划公告》，诸暨高特佳、重庆高特佳、杭州高特佳、杭 州睿泓计划通过集中竞价方式减持公司股份不超过93.57万股（含本数），不超过公司总股本的1.00%。 减持实施结果：四股东全额完成减持 合计套现约2275.67万元 公告强调，本次减持严格遵 ...

（记者 曾健辉） 每经AI快讯，安必平1月9日晚间发布公告称，今日，公司收到股东诸暨高特佳、重庆高特佳、杭州高 特佳和杭州睿泓出具的《股份减持结果告知函》，上述主体通过集中竞价交易的方式合计减持935676 股，占公司总股本的1.00%。减持计划实施完毕 每经头条（nbdtoutiao）——独家对话特斯拉FSD跨美第一人：4400公里"零接管"，手没碰过方向盘！作 为激光雷达销售员，他为何站队马斯克的"纯视觉"？ ...

1 证券代码：688393 证券简称：安必平 公告编号：2026-002 广州安必平医药科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前,股东诸暨高特佳睿安投资合伙企业（有限合伙）（以 下简称"诸暨高特佳"）及其一致行动人重庆高特佳睿安股权投资基金合伙企业 （有限合伙）（以下简称"重庆高特佳"）、杭州高特佳睿海投资合伙企业（有 限合伙）（以下简称"杭州高特佳"）、杭州睿泓投资合伙企业（有限合伙）（以 下简称"杭州睿泓"）、董事王海蛟先生合计持有广州安必平医药科技股份有限 公司（以下简称"公司"或"安必平"）6,292,662 股，占公司总股本 6.7253%, 上述股份来源均为公司首次公开发行前股份，且已于 2021 年 8 月 20 日解除限售 后上市流通。 减持计划的实施结果情况 2025 年 11 月 6 日，公司在上海证券交易所网站（www.see.com.cn）披露了 《股东减持股份计划公告》（公告编号：20 ...